Sanofi (SAN):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Sanofi (SAN) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7231
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:149
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥68,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥102,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sanofi is a healthcare company that researches, develops, manufactures and markets a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. The R&D efforts of Sanofi include working on combination drugs to increase the effectiveness of treatments and advancing the formulation of new biologics to produce medicines with precision. It has operations across Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

Sanofi (SAN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Sanofi, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Sanofi, Medical Equipment, Deals By Market, 2012 to YTD 2018 11
Sanofi, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Sanofi, Medical Equipment, Deal Details 15
Asset Purchase 15
Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 15
Sanofi Plans to Acquire Medical Device Assets 16
Venture Financing 17
True North Therapeutics Raises USD45 Million in Series D Financing 17
Portal Instruments Raises USD25 Million in Series B Financing 18
Portal Instruments Raises USD11 Million in Series A Venture Financing 19
Private Equity 20
Advent International Acquires Zentiva from Sanofi for USD2.37 Billion 20
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 22
Partnerships 23
Ablynx Exercises Option for Licensing Agreement with Vectura 23
Sensile Medical, Sanofi and Verily Enter into Co-Development Agreement 24
Adaptive Biotechnologies Enters into Agreement with Sanofi 25
Berg Enters into Research Agreement with Sanofi 26
Bioverativ and Invicro Enter into Agreement 27
Sanofi and Voluntis Enter into Agreement 28
R-Health Enters into Agreement with Bioverativ 29
Sanofi and Verily Life Sciences Form Joint Venture 30
Global Genomics Enters into Research Agreement with Sanofi 31
Google Life Sciences Enters into Agreement with Sanofi 32
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 33
Sanofi Enters into Co-Development Agreement with Medtronic 34
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 35
HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 36
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 37
Merger 38
Sanofi Japan and Genzyme Japan Merge 38
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 39
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 40
Equity Offering 41
JHL Biotech Raises USD80 Million in Private Placement of Shares 41
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 42
Ablynx Raises USD57 Million in Private Placement of Shares 43
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 44
Debt Offering 45
Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 45
Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 46
Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 47
Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 48
Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 49
Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 50
Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 51
Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 52
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 53
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 54
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 55
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 56
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 57
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 58
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 59
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 60
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 62
Acquisition 63
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 63
Bioverativ Therapeutics Acquires True North Therapeutics 65
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 66
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 67
L’Oreal Plans To Sell Its Stake In Sanofi 68
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 69
Sanofi Completes Acquisition Of Pluromed 71
Sanofi – Key Competitors 72
Sanofi – Key Employees 73
Sanofi – Locations And Subsidiaries 75
Head Office 75
Other Locations & Subsidiaries 75
Joint Venture 89
Recent Developments 90
Strategy And Business Planning 90
Sep 13, 2018: Sanofi to refocus two global business units 90
Financial Announcements 91
Mar 28, 2018: Sanofi: Pre – quarterly R esults C ommunication 91
Nov 02, 2017: Sanofi: Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed 93
Jul 31, 2017: Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER 100
Jul 12, 2017: Sanofi: Pre-quarterly Results Communication 106
Apr 28, 2017: Sanofi Delivers Robust Q1 2017 Financial Results 108
Feb 08, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER 114
Corporate Communications 122
Jul 26, 2018: Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st 122
Jun 19, 2018: Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer 123
May 08, 2018: Sanofi Announces Appointment of Mr. Charles Billard as Chief Financial Officer and Key Managerial Personnel 124
Apr 24, 2018: Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 125
Mar 06, 2018: Sanofi’s Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director 126
Jan 19, 2018: Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee 127
Apr 12, 2017: Sanofi appoints Nikhilesh Kalra to lead Consumer Healthcare business for India and South Asia 128
Apr 11, 2017: Sanofi Announces Pre-quarterly Results Communication 129
Apr 05, 2017: Sanofi Appoints Bill Sibold Executive Vice President Sanofi Genzyme and Member of the Executive Committee 131
Mar 02, 2017: Sanofi’s Board of Directors Proposes Appointment of Melanie Lee, PhD and Bernard Charles as New Independent Directors 132
Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 133
Jan 30, 2017: Sanofi Appoints Kathleen Tregoning to Executive Committee and Executive Vice President, External Affairs 134
Legal and Regulatory 135
Dec 31, 2017: Sanofi reaches civil settlement with US SEC 135
Other Significant Developments 136
Jun 13, 2018: DTxDM – the Home of Validated Digital Healthcare, Announces Its Founding Partners at the Launch of the New Hub for Everyone Working in Digital Therapeutics and Digital Medicine 136
May 28, 2018: Beactica Signs Three-Year Extension Agreement With Sanofi 137
Apr 27, 2018: Sanofi: First-quarter 2018 Business EPS up 1.4% at CER 138
Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance 145
Nov 16, 2017: Blue Cross and Blue Shield Companies Partner with Onduo on Three State Pilot Programs to Address Diabetes 147
Sep 25, 2017: Innovation Health Announces Pilot Program with Sanofi to Improve Care Delivery for People Living with Type 2 Diabetes 148
Appendix 149
Methodology 149
About GlobalData 149
Contact Us 149
Disclaimer 149

List of Tables
Sanofi, Medical Equipment, Key Facts, 2017 2
Sanofi, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Sanofi, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Sanofi, Deals By Market, 2012 to YTD 2018 11
Sanofi, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Sanofi Acquires Beacon OptoFluidic Platform from Berkeley Lights 15
Sanofi Plans to Acquire Medical Device Assets 16
True North Therapeutics Raises USD45 Million in Series D Financing 17
Portal Instruments Raises USD25 Million in Series B Financing 18
Portal Instruments Raises USD11 Million in Series A Venture Financing 19
Advent International Acquires Zentiva from Sanofi for USD2.37 Billion 20
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 22
Ablynx Exercises Option for Licensing Agreement with Vectura 23
Sensile Medical, Sanofi and Verily Enter into Co-Development Agreement 24
Adaptive Biotechnologies Enters into Agreement with Sanofi 25
Berg Enters into Research Agreement with Sanofi 26
Bioverativ and Invicro Enter into Agreement 27
Sanofi and Voluntis Enter into Agreement 28
R-Health Enters into Agreement with Bioverativ 29
Sanofi and Verily Life Sciences Form Joint Venture 30
Global Genomics Enters into Research Agreement with Sanofi 31
Google Life Sciences Enters into Agreement with Sanofi 32
Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 33
Sanofi Enters into Co-Development Agreement with Medtronic 34
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 35
HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 36
Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 37
Sanofi Japan and Genzyme Japan Merge 38
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 39
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 40
JHL Biotech Raises USD80 Million in Private Placement of Shares 41
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 42
Ablynx Raises USD57 Million in Private Placement of Shares 43
Ablynx Completes Private Placement Of Shares For US$1.2 Million Upon Exercise Of Warrants 44
Sanofi Prices Public Offering of 3.375% Notes Due 2023 for USD1 Billion 45
Sanofi Prices Public Offering of 3.625% Notes Due 2028 for USD1 Billion 46
Sanofi Prices First Tranche of Public Offering of Notes Due 2020 for USD1.2 Billion 47
Sanofi Prices Sixth Tranche of Public Offering of 1.875% Notes Due 2038 for USD1.54 Billion 48
Sanofi Prices Fifth Tranche of Public Offering of 1.375% Notes Due 2030 for USD2.47 Billion 49
Sanofi Prices Second Tranche of Public Offering of Notes Due 2020 for USD0.6 Billion 50
Sanofi Prices Fourth Tranche of Public Offering of 1% Notes Due 2026 for USD1.9 Billion 51
Sanofi Prices Third Tranche of Public Offering of 0.5% Notes Due 2023 for USD2.2 Billion 52
Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 53
Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 54
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 55
Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 56
Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 57
Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 58
Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 59
Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 60
Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 62
Sanofi Acquires Bioverativ for USD11.5 Billion in Tender Offer 63
Bioverativ Therapeutics Acquires True North Therapeutics 65
Sofinnova Divests Its Stake In Ablynx For US$29.4 Million 66
Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 67
L'Oreal Plans To Sell Its Stake In Sanofi 68
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 69
Sanofi Completes Acquisition Of Pluromed 71
Sanofi, Key Competitors 72
Sanofi, Key Employees 73
Sanofi, Subsidiaries 75
Sanofi, Joint Venture 89

List of Figures
Sanofi, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Sanofi, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Sanofi, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Sanofi, Medical Equipment, Deals by Type, 2012 to YTD 2018 9
Sanofi, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Sanofi, Medical Equipment, Deals by Market, 2012 to YTD 2018 11

★海外企業調査レポート[Sanofi (SAN):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pakistan State Oil Co Ltd (PSO):企業の財務・戦略的SWOT分析
    Pakistan State Oil Co Ltd (PSO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Lockheed Martin Aeronautics Company:企業の戦略・SWOT・財務情報
    Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Perseus Mining Ltd:企業の戦略・SWOT・財務分析
    Perseus Mining Ltd - Strategy, SWOT and Corporate Finance Report Summary Perseus Mining Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Chugai Pharmaceutical Co Ltd (4519)-製薬・医療分野:企業M&A・提携分析
    Summary Chugai Pharmaceutical Co Ltd (Chugai), a subsidiary of Hoffmann-La Roche Ltd, is a provider of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of cancer; bone and joint diseases; renal diseases; immunology and infectious diseases and others. It al …
  • Vionx Energy Corp:電力:M&Aディール及び事業提携情報
    Summary Vionx Energy Corp (Vionx Energy), formerly Premium Power Corp, is a diversified company. The company provides traditional vanadium redox flow batteries and patented battery stack that employs various components including tanks of anolyte and catholyte fluids, power cell at the center of the …
  • ANGLE Plc (AGL):製薬・医療:M&Aディール及び事業提携情報
    Summary ANGLE Plc (ANGLE) is a medical diagnostic company that offers cancer diagnostics and foetal health products. The company develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention, treatment, and monitoring of …
  • Versantis AG-製薬・医療分野:企業M&A・提携分析
    Summary Versantis AG (Versantis), is a preclinical stage pharmaceutical company which offers new medicines and diagnostics for treating liver diseases. It’s lead pipeline product VS-01, capable of removing toxic agents from the organism and save patients from prescription and illicit drug overdoses. …
  • New York Power Authority:発電所・企業SWOT分析
    New York Power Authority - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Access Bio Inc (950130):医療機器:M&Aディール及び事業提携情報
    Summary Access Bio Inc (Access Bio) is a medical device company that research, develops, manufactures and markets in-vitro diagnostics tests, biosensor, and molecular diagnostic products. The company provides in vitro diagnostic technology such as immunochemical, biochemical and molecular products. …
  • Nasdaq, Inc. (NDAQ):企業の財務・戦略的SWOT分析
    Nasdaq, Inc. (NDAQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • National Grid USA Service Co Inc:企業の戦略的SWOT分析
    National Grid USA Service Co Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • 8point3 Energy Partners LP (CAFD):電力:M&Aディール及び事業提携情報
    Summary 8point3 Energy Partners LP (8point3 Energy) is a renewable energy company that owns, operates and acquires solar energy generation projects. The company offers operation and maintenance, project development, and technical services. It operates residential, commercial, industrial, and utility …
  • Bharti Infratel Ltd:企業の戦略・SWOT・財務分析
    Bharti Infratel Ltd - Strategy, SWOT and Corporate Finance Report Summary Bharti Infratel Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Berger Paints India Ltd (BERGEPAINT):企業の財務・戦略的SWOT分析
    Berger Paints India Ltd (BERGEPAINT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • PDL BioPharma Inc:企業の戦略的SWOT分析
    PDL BioPharma Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Centogene AG-製薬・医療分野:企業M&A・提携分析
    Summary Centogene AG (Centogene) is a provider of genetic testing services. The company offers genetic testing for rare hereditary disorders. It offers whole genome sequencing, whole exome sequencing, biomarker and biochemical testing; prenatal testing, DNA extraction and cell culture services. Cent …
  • Highmark Inc.:企業の戦略・SWOT・財務情報
    Highmark Inc. - Strategy, SWOT and Corporate Finance Report Summary Highmark Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Enerjisa Enerji Uretim AS:企業の発電所・SWOT分析2018
    Enerjisa Enerji Uretim AS - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • Kiwibank Limited:企業の戦略・SWOT・財務情報
    Kiwibank Limited - Strategy, SWOT and Corporate Finance Report Summary Kiwibank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Independent News & Media Plc:企業の戦略的SWOT分析
    Independent News & Media Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆